enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. New Drug Application - Wikipedia

   en.wikipedia.org/wiki/New_Drug_Application

   The documentation required in an NDA is supposed to tell "the drug’s whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged.” [2] Once approval of an NDA is obtained, the new ...

3. Non-disclosure agreement - Wikipedia

   en.wikipedia.org/wiki/Non-disclosure_agreement

   Many banking institutions maintain client privacy through confidentiality agreements. Some, akin to attorney–client privilege, offer banker–client privilege.. A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), or secrecy agreement (SA), is a legal contract or part of a contract ...

4. Praxis Precision Medicines Highlights 2025 Corporate Strategy ...

   lite.aol.com/tech/story/0022/20250112/9330570.htm

   Praxis anticipates filing the NDA for ulixacaltamide in 2025. Following positive results from Essential3, the Company plans to re-initiate a study of ulixacaltamide in Parkinson’s disease, where there is significant and unmet need for non-dopaminergic treatment options.

5. Prescription Drug User Fee Act - Wikipedia

   en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act

   In 2015, 132.5 full application equivalents (FAEs) were charged an application fee. FAEs are calculated by counting a full application as one FAE and an application not requiring clinical data or a clinical data supplement as half an FAE. An application that is withdrawn, or refused for filing, counts as one quarter of the original FAE.

6. Horizon's NDA for Procysbi New Dosage Form Accepted by FDA - AOL

   www.aol.com/news/horizons-nda-procysbi-dosage...

   For premium support please call: 800-290-4726 more ways to reach us

7. Tarsus Provides 2025 Update: Accelerating the Launch of ...

   lite.aol.com/tech/story/0022/20250113/9330721.htm

   A recorded version of the call will be available on the website shortly after the completion of the call and will be archived there for at least 90 days. About XDEMVY ® XDEMVY (lotilaner ophthalmic solution, 0.25%), formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the ...